MedPath

Alumis and Acelyrin Announce Merger Deal, Suspend Phase III Plans for Lonigutamab

• Alumis and Acelyrin have entered into a merger agreement, marking a significant consolidation in the biotechnology sector.

• The companies announced the suspension of the planned Phase III program for lonigutamab following disappointing Phase II results reported in January.

• The merger decision includes a strategic reassessment of lonigutamab's development program to evaluate its potential value and future direction.

In a significant development in the biotechnology sector, Alumis has announced its plans to merge with Acelyrin, while simultaneously revealing the suspension of the planned Phase III clinical program for lonigutamab, Acelyrin's lead drug candidate.

Strategic Merger and Program Review

The merger announcement comes at a critical juncture for both companies, as they navigate the challenges of drug development and market dynamics. The decision to pause the Phase III program follows underwhelming Phase II results for lonigutamab that were reported in January, prompting a careful reassessment of the drug's development trajectory.

Clinical Development Status

The suspension of lonigutamab's Phase III program represents a significant shift in the development strategy. The companies will conduct a comprehensive evaluation of the drug candidate's value proposition, taking into account the Phase II results that failed to meet expectations. This reassessment will help determine the future direction of the program and potential modifications to the development strategy.

Market Implications

The merger between Alumis and Acelyrin reflects the ongoing consolidation trends in the biotechnology industry, where companies often combine resources and expertise to strengthen their market position and development capabilities. The decision to pause the lonigutamab program demonstrates a pragmatic approach to pipeline management, prioritizing careful evaluation over rushed development.

Development Strategy

The companies' decision to pause and reassess the lonigutamab program highlights the importance of data-driven decision-making in drug development. This strategic pause will allow for a thorough analysis of the Phase II results and enable the merged entity to make informed decisions about the program's future direction.
The merger and program review come at a time when biotechnology companies are increasingly focused on optimizing their research and development investments. The combined expertise of both companies will be crucial in determining the best path forward for lonigutamab and other pipeline assets.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Alumis and Acelyrin Announce Merger to Create $737M Clinical-Stage Biopharma Company

Alumis and Acelyrin have agreed to merge in an all-stock transaction, creating a combined entity with $737 million in cash runway extending into 2027.
The merged company will retain the Alumis name and prioritize development of two TYK2 inhibitors targeting conditions including psoriasis, lupus, and multiple sclerosis.

Alterity Therapeutics Halts Trading Ahead of Critical Phase II Neurodegenerative Disease Trial Results

Alterity Therapeutics has implemented a trading halt on its securities pending the announcement of results from a crucial Phase II clinical trial. The halt will remain in effect until the results are disclosed or until trading resumes on January 30, 2025, marking a significant moment for the biotechnology company's neurodegenerative disease program.

Apollomics' Uproleselan Fails Phase 3 Trial in Relapsed/Refractory AML

Apollomics' Phase 3 trial of uproleselan in China did not meet its primary endpoint, showing no significant benefit in overall survival for patients with relapsed or refractory AML.
The median overall survival in the uproleselan arm was 9.3 months, compared to 14.3 months in the chemotherapy-only arm, indicating a potential detriment with the addition of uproleselan.

Acelyrin's Lonigutamab Shows Promise in Phase 2, Phase 3 Program Design Announced for Thyroid Eye Disease

Acelyrin's lonigutamab demonstrated clinically meaningful improvements in Thyroid Eye Disease (TED) symptoms, including proptosis, CAS, and diplopia, in Phase 2 trials.
The Phase 3 LONGITUDE program, consisting of two global trials, is set to begin in Q1 2025, evaluating lonigutamab's safety and efficacy with topline data expected in H2 2026.

Alector and AbbVie's AL002 Fails Phase II Alzheimer's Trial, Leading to Layoffs

Alector's AL002, an anti-TREM2 antibody being developed with AbbVie, failed to meet the primary endpoint in the Phase II INVOKE-2 study for Alzheimer's disease.
The trial did not demonstrate a significant slowing of clinical progression, nor did it show improvements in key secondary, functional, or biomarker endpoints.

Allogene Therapeutics Halts Enrollment in Leukemia Trial Cema-Cel Due to Slow Recruitment

Allogene Therapeutics stopped enrolling patients in its Phase 1 trial of cemacabtagene ansegedleucel (cema-cel) for relapsed or refractory chronic lymphocytic leukemia (CLL).
The decision was driven by slower-than-expected recruitment, influenced by the emergence of new treatment options for CLL patients.

EMA Confirms Negative Stance on Masitinib for Amyotrophic Lateral Sclerosis

The EMA has upheld its negative opinion on granting conditional marketing authorization for masitinib as an add-on treatment for amyotrophic lateral sclerosis (ALS).
The decision follows a re-examination request by AB Science after an initial rejection, with concerns raised about data analysis.

Acelyrin Re-prioritizes Pipeline After Mixed Izokibep Results, Shifts Focus to Lonigutamab

Acelyrin's Phase 3 trial of izokibep for hidradenitis suppurativa (HS) met its primary endpoint, with 33% of patients achieving HiSCR75 at Week 12 compared to 21% on placebo.
Despite positive results, Acelyrin will not advance izokibep for HS or psoriatic arthritis (PsA) due to competitive concerns and insufficient efficacy.

Acelyrin Shifts Focus to Thyroid Eye Disease Drug, Halts Further Investment in Izokibep

Acelyrin will discontinue development of izokibep for hidradenitis suppurativa and psoriatic arthritis despite positive trial data, due to strategic prioritization.
The company will now focus on lonigutamab, an experimental antibody treatment for thyroid eye disease, advancing directly to Phase 3 trials.

Relyvrio Fails Phase 3 Trial, Amylyx Considers Market Withdrawal

Amylyx Pharmaceuticals' Relyvrio failed to demonstrate significant benefit in the Phase 3 PHOENIX trial for ALS, raising concerns about its efficacy.
The trial did not meet its primary endpoint of improving ALS functional scale or secondary endpoints like quality of life and overall survival.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy